Gregg Newman, MD
Hematology & Oncology · Santa Barbara, CANPI 1275645053
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Deciphera Pharmaceuticals Inc. at 51.1% of the total. Reporting peaked in 2021 at $2,495 and has fallen 89.7% since, to $257 in 2025.
Across 97 payments — averaging $47.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$2K
- AstraZeneca$374
- Johnson & Johnson$202
- EMD Serono, Inc.$185
- Pfizer$156
- Novartis$155
- plus $1K from 28 others
Across 334 payments — averaging $5070.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$680K
- Novartis$496K
- Eli Lilly$213K
- Bristol Myers Squibb$113K
- Janssen Research & Development, LLC$112K
- Mirati Therapeutics, Inc.$43K
- plus $35K from 5 others
What the payments were for
- Speaking & faculty fees$2,51654%
- Food & beverage$1,98743%
- Education$1052%
- Other$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 1 | $2,365 |
| AstraZeneca(2 entities) | 15 | $374 |
| Johnson & Johnson | 11 | $202 |
| EMD Serono, Inc. | 11 | $185 |
| Pfizer | 7 | $156 |
| Novartis | 7 | $155 |
| Foundation Medicine, Inc. | 1 | $151 |
| Adaptive Biotechnologies Corporation | 4 | $115 |
| Sumitomo Pharma America, Inc. | 1 | $106 |
| AbbVie | 4 | $81 |
| Seagen Inc. | 4 | $80 |
| Incyte Corporation | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Melinta Therapeutics, LLC | 2 | $43 |
| Agios Pharmaceuticals, Inc. | 2 | $42 |
| GSK | 2 | $37 |
| Lilly USA, LLC | 2 | $36 |
| ADC Therapeutics America, Inc. | 2 | $36 |
| Portola Pharmaceuticals, LLC | 1 | $32 |
| Merck | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Beigene USA, Inc. | 1 | $26 |
| Rigel Pharmaceuticals, Inc. | 1 | $25 |
| Bristol Myers Squibb | 1 | $24 |
| EUSA Pharma (US) LLC | 1 | $24 |
| Flowonix Medical Incorporated | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Welch Allyn | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Mckesson Specialty Care Distribution, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QINLOCK$2,365
- FOUNDATIONONE$151
- FOUNDATIONONE HEME$151
- FOUNDATIONONE CDX$151
- FOUNDATIONFOCUS$151
- FOUNDATIONONE LIQUID$151
- ORGOVYX$106
How this compares
$4,625 in reported general payments places this provider in the 55th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 58 | $832,274 |
| XtandiEnzalutamide | 38 | $599,246 |
| RevlimidLenalidomide | 28 | $545,083 |
| PomalystPomalidomide | 23 | $441,515 |
| JakafiRuxolitinib Phosphate | 27 | $433,384 |
| TagrissoOsimertinib Mesylate | 24 | $426,299 |
| NubeqaDarolutamide | 16 | $321,008 |
| MekinistTrametinib Dimethyl Sulfoxide | 18 | $318,704 |
| DopteletAvatrombopag Maleate | 12 | $275,365 |
| Lenalidomide | 26 | $247,038 |
| SprycelDasatinib | 15 | $166,779 |
| ImbruvicaIbrutinib | 13 | $151,506 |
| Abiraterone Acetate | 17 | $134,485 |
| VenclextaVenetoclax | 19 | $130,118 |
| EliquisApixaban | 58 | $53,442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $26 | $832,27458 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $16 | $608,29538 claims |
| Astellas Pharma US IncXtandi | $26 | $599,24638 claims |
| Bristol Myers SquibbRevlimid | $24 | $545,08328 claims |
| Incyte CorporationJakafi | $51 | $433,38427 claims |
| AstraZenecaTagrisso | $374 | $426,29924 claims |
| NovartisMekinist | $155 | $318,70418 claims |
| AbbVieVenclexta | $81 | $130,11819 claims |
| PfizerEliquis | $156 | $53,44258 claims |
| Johnson & JohnsonXarelto | $202 | $46,78244 claims |
| Lilly USA, LLCOlanzapine | $36 | $46820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Santa Barbara
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.